216 related articles for article (PubMed ID: 12430308)
1. [Primary and secondary failure of sulphonylureas].
Kanno H; Sakura H
Nihon Rinsho; 2002 Oct; 60 Suppl 10():719-23. PubMed ID: 12430308
[No Abstract] [Full Text] [Related]
2. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview.
Beck-Nielsen H; Hother-Nielsen O; Pedersen O
Diabet Med; 1988 Oct; 5(7):613-20. PubMed ID: 2975544
[No Abstract] [Full Text] [Related]
3. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?
Marble A
Drugs; 1971; 1(2):109-15. PubMed ID: 4999930
[No Abstract] [Full Text] [Related]
4. Cardiovascular effects of sulphonylureas: role of K(ATP) channels.
Howes LG
Diabetes Obes Metab; 2000 Apr; 2(2):67-73. PubMed ID: 11220526
[No Abstract] [Full Text] [Related]
5. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
Poltorak VV; Gladkikh AI
Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
[No Abstract] [Full Text] [Related]
6. [Clinical efficacy of glimepiride].
Kaneko T; Sakamoto N
Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
[No Abstract] [Full Text] [Related]
7. [Differential therapy using oral antidiabetics].
Mehnert H
Internist (Berl); 1971 Nov; 12(11):468-75. PubMed ID: 4943878
[No Abstract] [Full Text] [Related]
8. The pathogenesis of non-insulin-dependent diabetes: an update.
DeFronzo RA; Ferrannini E
Medicine (Baltimore); 1982 May; 61(3):125-40. PubMed ID: 7043155
[No Abstract] [Full Text] [Related]
9. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I--"The pros".
Waldhäusl W
Horm Metab Res; 1996 Sep; 28(9):517-21. PubMed ID: 8911990
[No Abstract] [Full Text] [Related]
10. [Structure and action mechanism of sulfonylurea].
Tasaka Y
Nihon Rinsho; 2002 Sep; 60 Suppl 9():333-8. PubMed ID: 12387014
[No Abstract] [Full Text] [Related]
11. [Prevention of the manifestation of diabetes mellitus through dietetic and drug measures. 1. Theoretical and clinical aspects with reference to the insulin findings in the peripheral venous blood].
Wüstenberg PW; Werner P; Dannenberg C; Michaelis D
Z Gesamte Inn Med; 1974 Mar; 29(6):221-7. PubMed ID: 4369652
[No Abstract] [Full Text] [Related]
12. [Sulfonylurea drugs for type 2 diabetes].
Toyota T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():339-45. PubMed ID: 12387015
[No Abstract] [Full Text] [Related]
13. The role of sulphonylureas in the management of type 2 diabetes mellitus.
Rendell M
Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
[TBL] [Abstract][Full Text] [Related]
14. Oral hypoglycemic agents.
Shen SW; Bressler R
Dis Mon; 1976 Jan; 22(4):1-35. PubMed ID: 765082
[No Abstract] [Full Text] [Related]
15. [Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives].
Tatoń J; Koliński P
Pol Tyg Lek; 1985 May; 40(18):505-11. PubMed ID: 3892513
[No Abstract] [Full Text] [Related]
16. Actual problems of the hypoglycaemic sulfonylureas.
Káldor A
Ther Hung; 1977; 25(2):47-50. PubMed ID: 898117
[No Abstract] [Full Text] [Related]
17. Oral hypoglycemic agents.
Boyden T; Bressler R
Adv Intern Med; 1979; 24():53-70. PubMed ID: 371368
[No Abstract] [Full Text] [Related]
18. Does insulin preserve beta-cell function in type 2 diabetes?
Heise T; Sawicki PT
J Intern Med; 2002 Apr; 251(4):283-5. PubMed ID: 11952878
[No Abstract] [Full Text] [Related]
19. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
Del Prato S; Pulizzi N
Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of insulin secretion and its modulation by sulfonylureas.
Panten U
Contrib Nephrol; 1989; 73():16-21; discussion 22-3. PubMed ID: 2689091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
